Eli Lilly & Co. and Incyte Corp. said they will seek U.S. emergency-use authorization for their rheumatoid-arthritis drug Olumiant as a treatment for Covid-19, after a study showed that it helped hospitalized patients recover sooner. Lilly and Incyte said Monday that adding Olumiant to remdesivir, a drug from Gilead Sciences Inc., shaved about one day off the median recovery time for Covid-19 patients, compared with patients who received remdesivir but not Olumiant.

Source: Wall Street Journal September 14, 2020 14:57 UTC